Professional Research
Robert W. Smith, M.D.

• Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• Co-investigator - VALIANT REGISTRY SUBSTUDY: VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• Sub-Investigator - EPHESUS - IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infaretion.
• Co-investigator - GUSTO IV AMI (Protocol C0116T31): A Phase III, randomized, open-label trial evaluating the efficacy and safety of. ReoPro™ (ABCIXIMAB) in combination with reduced dose Retavese™/Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.
• Co-investigator - AMISTAD 11 Trial (Phase 111): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarotion.
• Co-investigator - OCTAVE - CVI 37-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase 111, Randomized, Double Blind, Active Controlled Comparision of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension
• Co-investigator - REPLACE - TMC-BIV-00-01, Randomized Evaluation in Perouteneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.
• Co-investigator - CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease. To Monitor inflammatory markers
• Participant - ER-TIMI 19 - A Phase IV, Open-Label Trial of Prehospital Administration of Retavase® for ST elevation MI - the Early Retavase® (ER) - TIMI I9 Trial
• Co-Investigator - Amiodarone Aqueous I.V. Injection -A Double-Blind comparison of the Incidence of Hypotension with Two Formulations of Intravenous Amiodarone: Cordarone® I.V. VS Amiodarone Aqueous [.V. Injection. Protocol No. 0585KI-312-US.